NYSE:RCUS Arcus Biosciences Q2 2025 Earnings Report $9.15 -0.27 (-2.87%) Closing price 03:59 PM EasternExtended Trading$9.46 +0.31 (+3.38%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Arcus Biosciences EPS ResultsActual EPSN/AConsensus EPS -$1.14Beat/MissN/AOne Year Ago EPSN/AArcus Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AArcus Biosciences Announcement DetailsQuarterQ2 2025Date8/14/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Arcus Biosciences Earnings HeadlinesArcus Biosciences' Quemliclustat Gets Orphan Drug Status For ... - NasdaqJuly 12, 2025 | nasdaq.comArcus Biosciences’ cancer drug gets orphan drug statusJuly 11, 2025 | msn.comI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.July 18 at 2:00 AM | Timothy Sykes (Ad)Arcus Biosciences' Pancreatic Cancer Treatment Gets Orphan Drug StatusJuly 11, 2025 | marketwatch.comArcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic CancerJuly 11, 2025 | finance.yahoo.comArcus Biosciences' Quemliclustat Receives Orphan Drug Designation for Pancreatic CancerJuly 10, 2025 | gurufocus.comSee More Arcus Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email. Email Address About Arcus BiosciencesArcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Arcus’s lead product candidates target immune checkpoints and adenosine pathways, with the goal of improving efficacy and overcoming resistance observed with existing therapies. The company’s pipeline includes zimberelimab, a monoclonal anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; and etrumadenant, a dual A2A/A2B adenosine receptor antagonist. These candidates are being studied both as monotherapies and in combination regimens across a range of solid tumors. Arcus leverages translational biomarkers to guide patient selection and optimize dosing strategies in its ongoing global clinical trials. To advance its pipeline, Arcus has established strategic collaborations, including a partnership with Incyte to develop and commercialize its dual adenosine receptor antagonist program. The company also maintains clinical trial sites across North America, Europe and Asia, reflecting its commitment to broad patient access and global development. Founded in 2015 and headquartered in Hayward, California, Arcus Biosciences is led by a management team with extensive experience in oncology drug development. The company’s board and scientific advisory members bring deep expertise in immunology and translational medicine, supporting its mission to deliver transformative treatments for cancer patients worldwide.Written by Jeffrey Neal JohnsonView Arcus Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
